接受阿替利珠单抗-贝伐珠单抗治疗的肝细胞癌患者静脉曲张出血风险
韩国两家医院640例晚期肝细胞癌患者在内镜筛查后接受阿替利珠单抗-贝伐珠单抗治疗,中位随访5.6个月期间45例(7.0%)发生静脉曲张出血,6个月和12个月累积发生率分别为6.3%和7.4%,无患者死于静脉曲张出血;主门静脉侵犯、低血小板计数、胃肠道出血史和需治疗的静脉曲张是静脉曲张出血的显著危险因素。
要点
- 阿替利珠单抗-贝伐珠单抗治疗患者中位随访5.6个月静脉曲张出血累积发生率为6.3%(6个月)和7.4%(12个月)。
- 主门静脉侵犯(SHR 3.49)、胃肠道出血史(SHR 3.70)和需治疗的静脉曲张(SHR 2.67)增加静脉曲张出血风险。
- 低血小板计数亦与静脉曲张出血风险升高相关(SHR 0.994)。
核心结论
- 低血小板计数、主门静脉侵犯、胃肠道出血史和需治疗的静脉曲张是接受阿替利珠单抗-贝伐珠单抗治疗的肝细胞癌患者发生静脉曲张出血的显著危险因素。
研究设计与样本
- 回顾性研究,纳入韩国两家医院640例在接受阿替利珠单抗-贝伐珠单抗治疗前接受内镜检查的肝细胞癌患者。
主要发现
- 640例患者平均年龄61.3岁,男性528例(82.5%),主要病因为慢性乙型肝炎病毒(69.5%),BCLC C期563例(88.0%),门静脉侵犯313例(48.9%)。
- 中位随访5.6个月期间45例(7.0%)发生静脉曲张出血,6个月累积发生率为6.3%,12个月为7.4%,无患者死于静脉曲张出血。
- 多变量分析显示主门静脉侵犯(SHR 3.49,95%CI 1.63-7.44)、低血小板计数(SHR 0.994,95%CI 0.99-1.00)、胃肠道出血史(SHR 3.70,95%CI 1.49-9.16)和需治疗的静脉曲张(SHR 2.67,95%CI 1.26-5.64)增加静脉曲张出血风险。
临床怎么用
- 作者认为识别这些因素可指导临床医生在临床实践中评估和管理静脉曲张出血风险。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Real-world data on the variceal bleeding (VB) risk in patients receiving atezolizumab-bevacizumab (Atezo-Bev) treatment remain limited. This study aimed to assess the risk of VB and identify risk factors in patients with advanced hepatocellular carcinoma (HCC) receiving Atezo-Bev treatment. METHODS: This retrospective study included 640 patients with HCC who underwent endoscopy before Atezo-Bev treatment at two hospitals in Korea. The primary outcome was the occurrence of VB, with non-VB events considered as competing events. RESULTS: Of the 640 patients, the mean age was 61.3 years, and 528 (82.5%) patients were male. The main aetiology of HCC was chronic hepatitis B virus (69.5%), and 563 (88.0%) had BCLC stage C. Portal vein invasion (PVI) was present in 313 (48.9%). During a median follow-up of 5.6 months, 45 (7.0%) patients developed VB. The cumulative incidence of VB was 6.3% at 6 months and 7.4% at 12 months. No patient died from VB. Multivariable analysis revealed that the main PVI (subdistribution hazard ratio [SHR]: 3.49, 95% confidence interval [CI]: 1.63-7.44), low platelet count (SHR: 0.994, 95% CI: 0.99-1.00), a history of gastrointestinal (GI) bleeding (SHR: 3.70, 95% CI: 1.49-9.16) and varices needing treatment (VNT; SHR: 2.67, 95% CI: 1.26-5.64) increased the risk of VB. CONCLUSION: A low platelet count, main PVI, history of GI bleeding and VNT were significant risk factors for VB in patients receiving Atezo-Bev treatment for HCC. Identifying these factors can guide clinicians in assessing and managing VB risk in clinical settings.
引用
- Park K, Lee HW, Kim E, et al. Risk of Variceal Bleeding in Patients Receiving Atezolizumab-Bevacizumab Treatment for Hepatocellular Carcinoma. Aliment Pharmacol Ther. 2025. PMID: 39871662. doi:10.1111/apt.18526
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。